PMDAsafety guidance83% confidence
PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted
Source: PMDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Novartis.
Regulatory Analysis
PMDA regulatory document relevant to this signal.
Supporting Context
- Therapeutic area
- Neurology · Spinal Muscular Atrophy
- Sub-indication
- General
Related signal: Novartis initiates long-term follow-up study for OAV101 in Spinal Muscular Atrophy